Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00980343 · ClinicalTrials.gov registry record · Phase 2

GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

A Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
44
Enrollment target
9
Study locations

NCT00980343: Completed Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by National Cancer Institute (NCI).

NCT00980343 is a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants, roughly in line with the 41-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target. The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00980343, a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target
9
Study locations

Study Summary

This randomized phase II trial is studying how well GDC-0449 works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. GDC-0449 may be effective in treating patients with glioblastoma multiforme.

Primary Outcome

Estimated using Kaplan Meier curves. six months calculated from date of treatment onset post-operatively. MRI scan at 6 months must be free of progression Progressive disease Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.

Conditions Studied

Adult Glioblastoma Adult Giant Cell Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor

Interventions

  • OTHER laboratory biomarker analysis
  • PROCEDURE therapeutic conventional surgery
  • OTHER pharmacological study
  • DRUG vismodegib

Study Locations (9)

California

  • University of California at Los Angeles - Los Angeles
  • University of California San Francisco - San Francisco

Ohio

  • University Hospitals Case Medical Center - Cleveland
  • Cleveland Clinic Foundation - Cleveland

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • Henry Ford Hospital - Detroit

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Pennsylvania

  • University of Pennsylvania/Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2010-02
Est. Completion 2012-06
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00980343 record still lists

NCT00980343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, roughly in line with the 41-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target.

The record links to 4 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00980343 lists 9 locations in 7 states (California, Ohio, Georgia).

Frequently Asked Questions

What is clinical trial NCT00980343 about?

NCT00980343 is a clinical study titled "GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery". This randomized phase II trial is studying how well GDC-0449 works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. GDC-0449 may be effective in treating patients with glioblastoma multiforme.

What is the current status of trial NCT00980343?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2010-02. Estimated completion is 2012-06.

What conditions does trial NCT00980343 study?

This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor.

What interventions are being tested in trial NCT00980343?

The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic conventional surgery (PROCEDURE), pharmacological study (OTHER), vismodegib (DRUG).

Who is sponsoring clinical trial NCT00980343?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00980343 being conducted?

This trial has 9 study locations across California, Georgia, Massachusetts, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adult Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00980343's enrollment target sits among peer trials

44 6th of 14 higher than 9 of 14 other Adult Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Adult Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00980343, the US trial registry maintained by the National Library of Medicine. NCT00980343 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.